Home » Stocks » PerkinElmer

PerkinElmer, Inc. (United States) (PKI)

Stock Price: $119.05 USD -3.04 (-2.49%)
Updated Aug 6, 2020 4:03 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 13.26B
Revenue (ttm) 2.98B
Net Income (ttm) 225.81M
Shares Out 111.39M
EPS (ttm) 2.63
PE Ratio 45.27
Forward PE 24.69
Dividend $0.28
Dividend Yield 0.24%

Stock Quote

Trading Day Aug 6, 2020
Last Price $119.05
Previous Close $122.09
Change ($) -3.04
Change (%) -2.49%
Day's Open 122.07
Day's Range 118.21 - 122.58
Day's Volume 938,187
52-Week Range 62.91 - 123.21

More Stats

Market Cap 13.26B
Enterprise Value 15.27B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date Jul 16, 2020
Shares Outstanding 111.39M
Float 104.97M
EPS (basic) 2.04
EPS (diluted) 2.63
FCF / Share 3.17
Dividend $0.28
Dividend Yield 0.24%
Earnings Yield 2.21%
FCF Yield 2.65%
Payout Ratio 13.70%
Shares Short 2.78M
Short Ratio 3.03
Short % of Float 5.09%
Beta 1.42
PE Ratio 45.27
Forward PE 24.69
P/FCF Ratio 37.68
PS Ratio 4.46
PB Ratio 4.59
Revenue 2.98B
Operating Income 353.33M
Net Income 225.81M
Free Cash Flow 351.89M
Net Cash -2.00B
Net Cash / Share -18.00
Gross Margin 47.63%
Operating Margin 11.87%
Profit Margin 7.80%
FCF Margin 11.82%
ROA 4.53%
ROE 10.37%
ROIC 10.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (14)

Buy 3
Overweight 1
Hold 9
Underweight 1
Sell 0

Analyst Consensus: Overweight

Price Target

(3.25% upside)
Current: $119.05
Target: 122.92
*Average 12-month price target from 12 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth3.8%23.08%6.69%0.51%1.69%-4.07%2.49%9.73%12.74%-
Gross Profit1,3961,3411,0741,014964935976962848759
Operating Income36232429629525116522810391.13158
Net Income22823829323421215816769.947.66391
Shares Outstanding111111110110112113112115113118
Earnings Per Share2.042.132.642.121.871.391.470.610.073.31
EPS Growth-4.23%-19.32%24.53%13.37%34.53%-5.44%140.98%771.43%-97.89%-
Dividend Per Share0.280.280.350.
Dividend Growth0%-20%25%0%0%0%0%0%0%-
Operating Cash Flow363311288351287282159152225164
Capital Expenditures-76.33-93.25-39.09-31.70-28.22-24.6213.22-42.40-30.14-22.63
Free Cash Flow287218249319259257172110195142
Cash & Equivalents192163202359238175173171142420
Total Debt2,2201,8912,0061,0461,0131,046935941945426
Net Cash / Debt-2,029-1,728-1,804-687-775-872-761-769-803-6.17
Book Value2,8142,5852,5032,1542,1102,0421,9941,9401,8421,925
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name PerkinElmer, Inc. (United States)
Country United States
Employees 13,000
CEO Prahlad Ramadhar Singh

Stock Information

Ticker Symbol PKI
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NYSE: PKI


PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophym, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.